Cytokeratin 10 Mouse, Clone: SPM261, Novus Biologicals™

Cytokeratin 10

Western Blot 0.25-0.5ug/ml, Flow Cytometry 0.5-1ug/million cells, Immunocytochemistry/Immunofluorescence 0.5-1ug/ml, Immunoprecipitation 0.5-1ug/500ug protein lysate, Immunohistochemistry-Paraffin 0.5-1.0ug/ml, Immunohistochemistry-Frozen 0.5-1.0ug/ml

Monoclonal

Purified

RUO

Human, Mouse

P13645

3858

Skin extract of a human Psoriasis patient

Primary

Store at 4C.

56.5 kDa

SPM261

Western Blot, Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunoprecipitation, Immunohistochemistry (Paraffin)

Unconjugated

Mouse

Cytoskeleton Markers

PBS with 0.05% BSA. with 0.05% Sodium Azide

BCIE, BIE, CK10, CK-10, cytokeratin 10, Cytokeratin-10, EHK, K10keratosis palmaris et plantaris, keratin 10, Keratin 10 (epidermolytic hyperkeratosis; keratosis palmaris et plantaris), keratin, type I cytoskeletal 10, keratin-10, KPP

KRT10

IgG1 κ

Protein G purified

This MAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.